Oral human papillomavirus (HPV) infection and HPV vaccination in an Australian cohort.
HPV vaccination
oral human papillomavirus (HPV) infection
risk factors
sexual behaviour
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 07 2023
15 07 2023
Historique:
revised:
13
03
2023
received:
17
11
2022
accepted:
14
03
2023
medline:
15
5
2023
pubmed:
22
3
2023
entrez:
21
3
2023
Statut:
ppublish
Résumé
Human papillomavirus (HPV)-related oropharyngeal cancer (OPC) is increasing in incidence, yet very little is known about oral HPV infection in the general population. In this Australian-based study we assess oral HPV prevalence according to HPV vaccination status. Participants of the Oral Diversity Study were Australian residents, aged 18 to 70 years, who filled out a questionnaire about lifestyle and sexual behaviour, and donated a saliva sample in 2020 to 2021. We obtained permission to access HPV vaccination status through record linkage with the Australian Immunisation Register. Saliva samples were DNA extracted, DNA quality checked and analysed for HPV. We recruited 1023 participants to the Oral Diversity Study. Nine hundred twenty-one returned a saliva sample for analysis, 911 passed the DNA quality check and were included in the study. The oral HPV prevalence was 7.2%, and was strongly associated with sexual behaviours. We identified 27 different HPV types; 53% of participants carried high-risk HPV types, with no difference between the vaccinated and the unvaccinated groups (53% both, P = .979). Two hundred thirty participants (26%) were HPV vaccinated. The oral prevalence of the nine HPV types included in the nonavalent HPV vaccine was significantly lower in the vaccinated participants compared to the unvaccinated (0.9% vs 3.4%; P = .022). These findings suggest that a sizeable minority of Australian residents harbour oral HPV infections, and many of these are high-risk subtypes. We found some evidence that HPV vaccination resulted in lower prevalence of oral HPV infections of vaccine-specific types. Larger surveys are required to confirm these findings.
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
417-426Informations de copyright
© 2023 UICC.
Références
Hocking JS, Stein A, Conway EL, et al. Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers. Br J Cancer. 2011;104:886-891.
Hong A, Lee CS, Jones D, et al. Rising prevalence of human papillomavirus-related oropharyngeal cancer in Australia over the last 2 decades. Head Neck. 2016;38:746-750.
D'Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis. 2009;199:1263-1269.
Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst. 2008;100:407-420.
Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92:709-720.
Hong AM, Grulich AE, Jones D, et al. Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets. Vaccine. 2010;28:3269-3272.
Kolesnik M, Stepien E, Polz-Dacewicz M. Prevalence of human papillomavirus (HPV) in the oral cavity of a healthy population in south-eastern Poland. Int J Environ Res Public Health. 2022;19:7213.
Pauli S, Kops NL, Bessel M, et al. Sexual practices and HPV infection in unvaccinated young adults. Sci Rep. 2022;12:12385.
Wong MCS, Vlantis AC, Liang M, et al. Prevalence and epidemiologic profile of oral infection with alpha, beta, and gamma papillomaviruses in an Asian Chinese population. J Infect Dis. 2018;218:388-397.
Schnelle C, Whiteman DC, Porceddu SV, Panizza BJ, Antonsson A. Past sexual behaviors and risks of oropharyngeal squamous cell carcinoma: a case-case comparison. Int J Cancer. 2017;40:1027-1034.
Emmett S, Boros S, Whiteman DC, Porceddu SV, Panizza BJ, Antonsson A. Sexual behaviour, HPV status and p16(INK4a) expression in oropharyngeal and oral cavity squamous cell carcinomas: a case-case comparison study. J Gen Virol. 2018;99:783-789.
D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356:1944-1956.
Schwartz SM, Daling JR, Doody DR, et al. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst. 1998;90:1626-1636.
Smith EM, Ritchie JM, Summersgill KF, et al. Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst. 2004;96:449-455.
Olsen CM, Green AC, Neale RE, et al. Cohort profile: the QSkin Sun and Health Study. Int J Epidemiol. 2012;41:929-i.
Antonsson A, Cornford M, Perry S, Davis M, Dunne MP, Whiteman DC. Prevalence and risk factors for oral HPV infection in young Australians. PLoS One. 2014;9:e91761.
Antonsson A, de Souza M, Wood ZC, et al. Natural history of oral HPV infection: longitudinal analyses in prospective cohorts from Australia. Int J Cancer. 2021;148:1964-1972.
de Roda Husman AM, Walboomers JM, Hopman E, et al. HPV prevalence in cytomorphologically normal cervical scrapes of pregnant women as determined by PCR: the age-related pattern. J Med Virol. 1995;46:97-102.
Agresti A, Coull BA. Approximate is better than ‘exact’ for interval estimation of binomial proportions. Am Stat. 1998;52:119-126.
Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA. 2012;307:693-703.
Edelstein ZR, Schwartz SM, Hawes S, et al. Rates and determinants of oral human papillomavirus infection in young men. Sex Transm Dis. 2012;39:860-867.
Kreimer AR, Villa A, Nyitray AG, et al. The epidemiology of oral HPV infection among a multinational sample of healthy men. Cancer Epidemiol Biomarkers Prev. 2011;20:172-182.
Abel MK, Mann AK, Sonawane K, Kapp DS, Deshmukh AA, Chan JK. Prevalence of oral human papillomavirus infection by number of vaccine doses among US adults. JNCI Cancer Spectr. 2021;5:5.
Chaturvedi AK, Graubard BI, Broutian T, et al. Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. J Clin Oncol. 2018;36:262-267.
Meites E, Winer RL, Newcomb ME, et al. Vaccine effectiveness against prevalent anal and oral human papillomavirus infection among men who have sex with men-United States, 2016-2018. J Infect Dis. 2020;222:2052-2060.
Castillo A, Osorio JC, Fernandez A, et al. Effect of vaccination against oral HPV-16 infection in high school students in the city of Cali Colombia. Papillomavirus Res. 2019;7:112-117.
Beachler DC, Kreimer AR, Schiffman M, et al. Multisite HPV16/18 vaccine efficacy against cervical, anal, and oral HPV infection. J Natl Cancer Inst. 2016;108:djv302.
Herrero R, Quint W, Hildesheim A, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One. 2013;8:e68329.